An FDA advisory panel voted to loosen restrictions on some experimental peptides, and Gladstone Institutes president Deepak Srivastava is warning about it.
Recap by typeshit. Post by Gladstone Institutes on X.
The pharmacy boards group, per InsideHealthPolicy, ties reported deaths linked to retatrutide to weak enforcement against gray-market peptide sellers.
Judge Raphael Leite Guedes in Maranhão found tirzepatide counts as a home-use drug under Law 9,656/98, even when a clinic gives the shots.
Inc. reports that some Georgia clinics are still marketing an unapproved Lilly weight loss drug even as the company moves against its sale.
After advisers backed adding BPC-157, TB-500, KPV and others to the 503A bulks list, pharmacists are waiting on the FDA's final decision.
13:47
Ketcham runs through the habits she credits for her 90 pound loss on tirzepatide. Her personal take, not medical advice, so check with a doctor.
9:07
The endocrinologist takes on whether people can get retatrutide now, setting gray market supply against the results from Lilly's actual trials.
Loading…